Disclosure NewswireTMiCrowdNewswire - Sep 20, 2016
BEDMINSTER, NJ – CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, announced today that its executives have been invited to speak at upcoming scientific, investor and industry conferences.
Event: 16th Annual Biotech in Europe Forum for Global Partnering and Investment Company presentation; participation in Vaccines & Infectious Diseases panel
Date: September 27-28, 2016
Location: Congress Center Basel, Switzerland
Event: Dawson James 2016 Growth Conference
Date: October 20, 2016
Location: Wyndham Grand Jupiter at Harbourside Place, Jupiter, Florida
Event: NY/ NJ CEO Conference
Date: November 2-3, 2016
Location: Apella at Alexandria Center, New York
Event: BIO Europe Conference
Date: November 7-9, 2016
Location: KoelnMesse – Congress Center North, Cologne, Germany
CorMedix executives will provide an overview of the company’s business during live presentations and will also be available to participate in one-on-one meetings with investors who are registered to attend the conferences.
About CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin is currently in a Phase 3 clinical study in patients undergoing chronic hemodialysis via a central venous catheter. The company is planning to conduct its second Phase 3 study in patients with cancer receiving IV parenteral nutrition, chemotherapy and hydration via a chronic central venous catheter, subject to sufficient resources. If successful, the two pivotal studies may be submitted to the FDA for potential approval for both patient populations. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, contributing to potentially accelerated FDA review and up to 10 years of market exclusivity upon potential U.S. approval. It is already a CE Marked product in Europe and other territories. CorMedix is also seeking to unlock additional value for its taurolidine-based technology by establishing collaborative partnerships in oncology and medical device applications. For more information visit: www.cormedix.com.
For Investors & Media: